在帕金森病中出现多巴胺失调综合征
11Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, California.
The Senior care pharmacist
|November 11, 2025
概括
患有帕金森病 (PD) 的患者可以通过滥用多巴胺治疗来发展多巴胺失调综合征 (DDS). 这一案例凸显了当Mucuna pruriens补充剂与处方卡比多巴/莱沃多巴结合使用时,DDS的风险.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 补充医学是一种补充医学.
背景情况:
- 帕金森病 (PD) 的管理通常涉及多巴胺替代疗法.
- 多巴胺失调综合征 (DDS) 是多巴胺治疗的公认并发症.
- ,一种天然的利沃多巴来源,有时被PD患者使用.
研究的目的:
- 在帕金森病患者中描述DDS病例.
- 检查Mucuna pruriens在DDS发展中的作用.
- 强调监测PD患者药物使用的重要性.
主要方法:
- 案例研究方法.
- 对患者的药物 anamnesis 的审查,包括处方的 carbidopa/levodopa (ER/IR) 和自我给药的 Mucuna pruriens.
- 对多巴胺失调综合征症状的临床评估.
主要成果:
- 这位患者出现了多巴胺失调综合征.
- 随着Mucuna pruriens与处方卡比多巴/莱沃多巴的同时使用后,DDS发生了.
- 观察到过度的自我指导剂量超出了运动症状控制.
结论:
- 同时使用Mucuna pruriens和处方的多巴胺疗法可以在帕金森病患者中加速DDS.
- 患者教育和警监测对于防止药物滥用至关重要.
- 医疗保健提供者应该意识到在PD管理中与补充药物相关的潜在相互作用和风险.
相关概念视频
Parkinson's Disease: Treatment
954
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
954
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
1.8K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.8K
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K


